lumateperone   Click here for help

GtoPdb Ligand ID: 9099

Synonyms: Caplyta® | ITI-007
Approved drug
lumateperone is an approved drug (FDA (2019))
Compound class: Synthetic organic
Comment: Lumateperone (ITI-007) is an antipsychotic, with a novel mechanism of action, making it the first-in class agent of its type [2,5]. Note that the approved drug contains lumateperone tosylate (PubChem CID 44241743).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 26.79
Molecular weight 393.22
XLogP 4.26
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cc1)C(=O)CCCN1CCC2C(C1)c1cccc3c1N2CCN3C
Isomeric SMILES Fc1ccc(cc1)C(=O)CCCN1CCC2C(C1)c1cccc3c1N2CCN3C
InChI InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3
InChI Key HOIIHACBCFLJET-UHFFFAOYSA-N
References
1. Jankowska A, Wesolowska A, Pawlowski M, Chlon-Rzepa G. (2018)
Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research.
Curr Med Chem, 25 (17): 2045-2067. [PMID:28554324]
2. Kumar B, Kuhad A, Kuhad A. (2018)
Lumateperone: a new treatment approach for neuropsychiatric disorders.
Drugs Today, 54 (12): 713-719. [PMID:30596390]
3. Li P, Zhang Q, Robichaud AJ, Lee T, Tomesch J, Yao W, Beard JD, Snyder GL, Zhu H, Peng Y et al.. (2014)
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.
J Med Chem, 57 (6): 2670-82. [PMID:24559051]
4. Snyder GL, Vanover KE, Zhu H, Miller DB, O'Callaghan JP, Tomesch J, Li P, Zhang Q, Krishnan V, Hendrick JP et al.. (2015)
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.
Psychopharmacology (Berl.), 232 (3): 605-21. [PMID:25120104]
5. Vyas P, Hwang BJ, Brašić JR. (2020)
An evaluation of lumateperone tosylate for the treatment of schizophrenia.
Expert Opin Pharmacother, 21 (2): 139-145. [PMID:31790322]